Amneal Pharmaceuticals (AMRX) Liabilities and Shareholders Equity (2017 - 2026)

Amneal Pharmaceuticals' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $3.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 5.2% year-over-year to $3.5 billion; the TTM figure through Mar 2026 stood at $14.2 billion (up 2.92% YoY), while the FY2025 annual figure was $3.7 billion, up 5.05% from the prior year.
• Liabilities and Shareholders Equity was $3.5 billion for Q1 2026 at Amneal Pharmaceuticals, down from $3.7 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.0 billion in Q2 2022 to a low of $3.4 billion in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $3.6 billion across 5 years, with a median of $3.6 billion in 2025.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity fell 8.6% in 2023, then grew 5.2% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $3.8 billion in 2022, then declined by 8.6% to $3.5 billion in 2023, then rose by 0.83% to $3.5 billion in 2024, then increased by 5.05% to $3.7 billion in 2025, then dropped by 3.75% to $3.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $3.5 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.